study_id	test_name	manufacturer	country	n_samples_true_neg	n_test_neg_out_of_true_neg	n_samples_true_pos	n_test_pos_out_of_true_pos	specificity	sensitivity	validated_during_serosurvey	ref	positive_validation_samples	negative_validation_samples	comments	n_samples_true_neg2	n_test_neg_out_of_true_neg2	n_samples_true_pos2	n_test_pos_out_of_true_pos2	sensitivity2	specificity2	validated_during_serosurvey2	ref2	positive_validation_samples2	negative_validation_samples2	comments2
BRA1	Wondfo SARS-CoV-2 antibody test							0.99	0.848					Authors state that: "pooling the results from the four validation studies, weighted by sample sizes, sensitivity is estimated at 84.8% (95% CI 81.4%;87.8%) and specificity at 99.0% (95% CI 97.8%;99.7%)."
CHE1	anti-SARS-CoV-2-IgG ELISA	Euroimmun AG, LÃ¼beck, Germany # EI 2606-9601 G	Switzerland	176	176	181		1	0.862	yes	https://www.medrxiv.org/content/10.1101/2020.05.02.20088898v1.full.pdf	rt-pcr positive covid patients	pre pandemic negative controls	Published seroprevalence estimates. Set own threshold for positivity: OD/CI >= 1.5
DNK1	IgM/IgG Antibody to SARS-CoV-2, lateral flow test	Livzon Diagnostics Inc	Denmark	651	648	155	128	0.994623656	0.825806452	yes	https://www.medrxiv.org/content/10.1101/2020.04.24.20075291v1.full.pdf	clinical covid patients	blood donors giving blood before November 2019	1 sample inconclusive on the serology validation on true negatives. Included as 0.5
ESP1-2	Orient Gene IgM/IgG	Zhejiang Orient Gene Biotech	Spain	156	156	153	123	1	0.803921569	yes	https://www.mscbs.gob.es/ciudadanos/ene-covid/home.htm, accessed 152/06/2020	rt-pcr positive covid patients (could be self reported postiives? Not clear)	not given		80		29		0.931	100		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178815/	rt-pcr positive covid patients	pre pandemic negative controls	ignore the reported 99% specificity, which includes a post covid 'healthy' person (they may have really had covid?)
ESP2	Orient Gene IgM/IgG	Zhejiang Orient Gene Biotech	Spain	NA	NA	267		1	0.805	yes	https://www.mscbs.gob.es/ciudadanos/ene-covid/home.htm, accessed 152/06/2020	rt-pcr positive covid patients (could be self reported postiives? Not clear)	not given		80		29		0.931	100		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178815/	rt-pcr positive covid patients	pre pandemic negative controls	ignore the reported 99% specificity, which includes a post covid 'healthy' person (they may have really had covid?)
GBR1	ELISA detecting antibodies to spike protein		United Kingdom	100	100	7	6	1	0.857142857	yes		Seven control samples from contract-traced individuals who were PCRconfirmed as SARS-Cov-2 infected were used as positive controls in the study. All the individuals from whom the positive control sera samples were taken had asymptomatic SARS-CoV-2 infections	100 blood  donor samples were tested in parallel from the Scottish National Blood Transfusion Service (SNBTS) anonymous archive collected between September 2018 and December 2019
GBR2			United Kingdom					1	1					already adjusted in the seroprevalence presented
LA_CA
NLD1	SARS-CoV-2 total antibody ELISA	Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China	Netherlands	282	281	174	171	0.996453901	0.982758621	yes	https://www.researchsquare.com/article/rs-25862/v1	PCR-confirmed COVID-19 patients admitted to Dutch intensive care units in March 2020,  (n=10; 9/10 seropositive; 1/10 seronegative), (iii) Dutch PCR-confirmed COVID-19 patients with only mild symptoms (n=11; 11/11 seropositive), (iv) Dutch plasma donors with a documented PCR-positive test result who were at least 14 days fully recovered from mild or moderate COVID-19 symptoms	Dutch blood donors collected in March and April 2018 (n=282; 1/282 seropositive)
NLD2	SARS-CoV-2 total antibody ELISA	Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China	Netherlands	282	281	174	171	0.996453901	0.982758621	yes	https://www.researchsquare.com/article/rs-25862/v1	PCR-confirmed COVID-19 patients admitted to Dutch intensive care units in March 2020,  (n=10; 9/10 seropositive; 1/10 seronegative), (iii) Dutch PCR-confirmed COVID-19 patients with only mild symptoms (n=11; 11/11 seropositive), (iv) Dutch plasma donors with a documented PCR-positive test result who were at least 14 days fully recovered from mild or moderate COVID-19 symptoms	Dutch blood donors collected in March and April 2018 (n=282; 1/282 seropositive)
SWE1	unknown		Sweden	NA	NA	NA	NA	NA	NA	NA				seroprevalence from news report, test unknown											
